{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:27:27Z","timestamp":1771903647344,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017629","name":"Harmony Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"DOI":"10.1186\/s11689-025-09657-x","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:42:42Z","timestamp":1763466162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study"],"prefix":"10.1186","volume":"17","author":[{"given":"Elizabeth","family":"Berry-Kravis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Budimirovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline B.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Silove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Tich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Sebree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"O\u2019Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen G.","family":"Bzdek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Budur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"9657_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"RJ Hagerman","year":"2017","unstructured":"Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr., Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9657_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dmcn.13985","volume":"61","author":"CM Kraan","year":"2019","unstructured":"Kraan CM, Godler DE, Amor DJ. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev Med Child Neurol. 2019;61(2):121\u20137.","journal-title":"Dev Med Child Neurol"},{"key":"9657_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23041935","author":"DD Protic","year":"2022","unstructured":"Protic DD, Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, et al. Fragile X syndrome: from molecular aspect to clinical treatment. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23041935.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"9657_CR4","first-page":"129","volume":"166","author":"RJ Hagerman","year":"1997","unstructured":"Hagerman RJ. Fragile X syndrome. Molecular and clinical insights and treatment issues. West J Med. 1997;166(2):129\u201337.","journal-title":"West J Med"},{"issue":"5","key":"9657_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000329421","volume":"33","author":"MR Tranfaglia","year":"2011","unstructured":"Tranfaglia MR. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci. 2011;33(5):337\u201348.","journal-title":"Dev Neurosci"},{"issue":"1","key":"9657_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-023-09475-z","volume":"15","author":"JM Palumbo","year":"2023","unstructured":"Palumbo JM, Thomas BF, Budimirovic D, Siegel S, Tassone F, Hagerman R, et al. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. J Neurodev Disord. 2023;15(1):1.","journal-title":"J Neurodev Disord"},{"issue":"1","key":"9657_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-022-09466-6","volume":"14","author":"E Berry-Kravis","year":"2022","unstructured":"Berry-Kravis E, Hagerman R, Budimirovic D, Erickson C, Heussler H, Tartaglia N, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord. 2022;14(1):56.","journal-title":"J Neurodev Disord"},{"key":"9657_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00315","volume":"11","author":"F Navarrete","year":"2020","unstructured":"Navarrete F, Garcia-Gutierrez MS, Jurado-Barba R, Rubio G, Gasparyan A, Austrich-Olivares A, et al. Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry. 2020;11:315.","journal-title":"Front Psychiatry"},{"key":"9657_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114237","volume":"359","author":"DS Reddy","year":"2023","unstructured":"Reddy DS. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Exp Neurol. 2023;359:114237.","journal-title":"Exp Neurol"},{"issue":"14","key":"9657_CR10","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of Cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-11.","journal-title":"Neurology"},{"issue":"2","key":"9657_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","volume":"60","author":"O Devinsky","year":"2019","unstructured":"Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294\u2013302.","journal-title":"Epilepsia"},{"issue":"10","key":"9657_CR12","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/epi.17036","volume":"62","author":"IE Scheffer","year":"2021","unstructured":"Scheffer IE, Halford JJ, Miller I, Nabbout R, Sanchez-Carpintero R, Shiloh-Malawsky Y, et al. Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(10):2505\u201317.","journal-title":"Epilepsia"},{"issue":"2","key":"9657_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/epi.17150","volume":"63","author":"EA Thiele","year":"2022","unstructured":"Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, et al. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia. 2022;63(2):426\u201339.","journal-title":"Epilepsia"},{"key":"9657_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111575","author":"MS Garcia-Gutierrez","year":"2020","unstructured":"Garcia-Gutierrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10111575.","journal-title":"Biomolecules"},{"key":"9657_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.643442","volume":"12","author":"KA Kwan Cheung","year":"2021","unstructured":"Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and neurodevelopmental disorders in children. Front Psychiatry. 2021;12:643442.","journal-title":"Front Psychiatry"},{"issue":"1","key":"9657_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-019-9277-x","volume":"11","author":"H Heussler","year":"2019","unstructured":"Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019;11(1):16.","journal-title":"J Neurodev Disord"},{"issue":"3","key":"9657_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF01048240","volume":"22","author":"EC Marshburn","year":"1992","unstructured":"Marshburn EC, Aman MG. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord. 1992;22(3):357\u201373.","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"9657_CR18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","volume":"42","author":"SM Sansone","year":"2012","unstructured":"Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377\u201392.","journal-title":"J Autism Dev Disord"},{"key":"9657_CR19","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/j.biopsych.2021.02.368","volume":"89","author":"E Merikle","year":"2021","unstructured":"Merikle E, Patel V, Dobbins T, O\u2019Quinn S, Tich N, Palumbo JM. Cannabidiol in fragile X syndrome (FXS): proposed mechanism of action (MOA) translates into meaningful clinical benefits [CONNECT-FX (ZYN2-CL-016)]. Biol Psychiatry. 2021;89:S143.","journal-title":"Biol Psychiatry"},{"key":"9657_CR20","doi-asserted-by":"crossref","unstructured":"Merikle E, Patel VP, Dobbins T, Griesser J, Tich N, Sebree T, et al. Meaningful change thresholds for the aberrant behavior Checklist-Community fragile X syndrome (ABC-CFXS) in children and adolescents with FXS. Poster presented at: international society for pharmacoeconomics and outcomes research (ISPOR) 2021. Virtual; 2021.","DOI":"10.1016\/j.jval.2021.04.986"},{"issue":"1","key":"9657_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01813-w","volume":"19","author":"H Staunton","year":"2021","unstructured":"Staunton H, Trennery C, Arbuckle R, Guridi M, Zhuravleva E, Furlong P, et al. Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy. Health Qual Life Outcomes. 2021;19(1):184.","journal-title":"Health Qual Life Outcomes"},{"key":"9657_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","volume":"35","author":"I Katona","year":"2012","unstructured":"Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012;35:529\u201358.","journal-title":"Annu Rev Neurosci"},{"issue":"2","key":"9657_CR23","first-page":"153","volume":"30","author":"Z Mouslech","year":"2009","unstructured":"Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30(2):153\u201379.","journal-title":"Neuro Endocrinol Lett"},{"key":"9657_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/3-540-26573-2_12","volume":"168","author":"CW Vaughan","year":"2005","unstructured":"Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol. 2005;168:367\u201383.","journal-title":"Handb Exp Pharmacol"},{"key":"9657_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2045","volume":"3","author":"KM Jung","year":"2012","unstructured":"Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080.","journal-title":"Nat Commun"},{"issue":"1607","key":"9657_CR26","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1098\/rstb.2011.0387","volume":"367","author":"M Reisenberg","year":"2012","unstructured":"Reisenberg M, Singh PK, Williams G, Doherty P. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3264\u201375.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7","key":"9657_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/npp.2010.19","volume":"35","author":"M Maccarrone","year":"2010","unstructured":"Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor\/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology. 2010;35(7):1500\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"9657_CR28","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"9657_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737\u201353.","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"9657_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","volume":"456","author":"RG Pertwee","year":"2002","unstructured":"Pertwee RG, Ross RA, Craib SJ, Thomas A. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002;456(1\u20133):99\u2013106.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"9657_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1460-9568.2007.05448.x","volume":"25","author":"D Ryan","year":"2007","unstructured":"Ryan D, Drysdale AJ, Pertwee RG, Platt B. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci. 2007;25(7):2093\u2013102.","journal-title":"Eur J Neurosci"},{"issue":"5","key":"9657_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613\u201323.","journal-title":"Br J Pharmacol"},{"issue":"36","key":"9657_CR33","doi-asserted-by":"publisher","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","volume":"289","author":"RB Laprairie","year":"2014","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Dupre DJ, Denovan-Wright EM. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014;289(36):24845\u201362.","journal-title":"J Biol Chem"},{"issue":"8","key":"9657_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037\u201343.","journal-title":"Neurochem Res"},{"key":"9657_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","volume":"119","author":"T Bakas","year":"2017","unstructured":"Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res. 2017;119:358\u201370.","journal-title":"Pharmacol Res"},{"issue":"3","key":"9657_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"9657_CR37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","volume":"36","author":"KS Paudel","year":"2010","unstructured":"Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36(9):1088\u201397.","journal-title":"Drug Dev Ind Pharm"},{"issue":"21","key":"9657_CR38","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med"},{"issue":"20","key":"9657_CR39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"9657_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/can.2015.0004","volume":"1","author":"J Merrick","year":"2016","unstructured":"Merrick J, Lane B, Sebree T, Yaksh T, O\u2019Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1(1):102\u201312.","journal-title":"Cannabis Cannabinoid Res"},{"key":"9657_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/toxics8020041","author":"P Golombek","year":"2020","unstructured":"Golombek P, Muller M, Barthlott I, Sproll C, Lachenmeier DW. Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC): a controversy in the scientific literature. Toxics. 2020. https:\/\/doi.org\/10.3390\/toxics8020041.","journal-title":"Toxics"},{"issue":"1","key":"9657_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/can.2016.0038","volume":"2","author":"MO Bonn-Miller","year":"2017","unstructured":"Bonn-Miller MO, Banks SL, Sebree T, et al. Conversion of cannabidiol following oral administration: Authors\u2019 response to Grotenhermen. Cannabis Cannabinoid Res. 2017;2(1):5\u20137.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"9657_CR43","first-page":"5","volume":"90","author":"P Romita","year":"2018","unstructured":"Romita P, Foti C, Calogiuri G, Cantore S, Ballini A, Dipalma G, et al. Contact dermatitis due to transdermal therapeutic systems: a clinical update. Acta Biomed. 2018;90(1):5\u201310.","journal-title":"Acta Biomed"},{"issue":"9","key":"9657_CR44","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/bph.13059","volume":"172","author":"MN Pastore","year":"2015","unstructured":"Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015;172(9):2179\u2013209.","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:42:44Z","timestamp":1763466164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9657"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09657-x","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by Advarra, Inc. Institutional Review Board (IRB; Approval Number: Pro00060799.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EB-K, RH, JC, DB, CBB, and NS have received funding from Harmony Biosciences for the conduct of this trial as investigators. TD, TS, and SOQ are paid consultants of Harmony Biosciences. CBB is a paid consultant of Acadia Pharmaceuticals. NT, AT, DSA, KGB, GN, and KB are employees of Harmony Biosciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}